- ATHENA study evaluating Rubraca® (rucaparib) monotherapy versus
placebo (ATHENA-MONO) in first-line ovarian cancer maintenance
treatment successfully achieved the primary endpoint of improved
PFS in both populations in the primary efficacy analyses:
HRD-positive and all patients randomized (ITT)
- Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo
in ITT population
- Late-breaker data to be presented in oral session at 2022 ASCO
Annual Meeting on Monday, June 6
- Two additional top-line Phase 3 data read-outs for Rubraca
expected in next 12 months with potential to address ovarian and
prostate cancer patient populations
- Initial Phase 1 clinical data for targeted radiotherapy
candidate FAP-2286 to be presented in oral presentation at SNMMI
2022 Annual Meeting on Tuesday, June 14
- Initiation of Phase 2 expansion cohorts in multiple tumor types
anticipated in Q4 2022
- $34.2M in Rubraca global net product revenues for Q1 2022, down
10% vs Q1 2021 and down 5% vs Q4 2021
- Continued impact of COVID-19 on ovarian cancer diagnoses and
treatments
- Reduction in R&D expense of $10.6M or 20% compared to Q1
2021
- $122.2M in cash and cash equivalents and $18.6M in available
funding under the ATHENA financing at March 31, 2022
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results
for the quarter ended March 31, 2022, and provided an update on the
Company’s clinical development programs and regulatory and
commercial outlook.
“We entered 2022 knowing that it would be the most significant
year for clinical data read-outs in the Company’s history, and we
are obviously pleased that the results from the ATHENA-MONO study
of Rubraca, the first of those read-outs, exceeded our
expectations. Importantly, we believe that the positive results
from ATHENA-MONO, which will be described in full at ASCO next
month, demonstrate the benefit that Rubraca can provide as an
important new treatment option for women with advanced ovarian
cancer in the first-line maintenance setting,” said Patrick J.
Mahaffy, President and CEO of Clovis Oncology. “We continue to
anticipate two additional Phase 3 read-outs for Rubraca: TRITON3 in
second-line prostate cancer treatment for selected patients during
the third quarter this year, and ATHENA-COMBO in combination with
Opdivo in first-line ovarian cancer maintenance treatment in the
first quarter of 2023. Importantly, for our first targeted
radiotherapy candidate, FAP-2286, we look forward to presenting
initial data from the Phase 1 portion of the LuMIERE study at the
SNMMI Annual Meeting next month, and initiating the Phase 2 portion
of the study during the fourth quarter.”
First Quarter 2022 Financial Results
Clovis reported global net product revenues for Rubraca of $34.2
million for Q1 2022, which included US product revenues of $24.5
million and ex-US product revenues of $9.7 million. This represents
a 5% decrease over Q4 2021 and a 10% decrease year-over-year,
compared to Q1 2021 net product revenues of $38.1 million, which
included US net product revenues of $31.7 million and ex-US net
product revenues of $6.4 million. The decrease was primarily due to
fewer diagnoses and fewer patient starts in the US.
Research and development expenses totaled $42.3 million for Q1
2022, down 20% compared to $52.8 million for the comparable period
in 2021, due primarily to lower spending on Rubraca clinical
trials. Clovis expects research and development expenses in the
full year 2022 to be comparable to 2021.
Selling, general and administrative expenses totaled $29.2
million for Q1 2022, down 2% compared to $29.9 million for the
comparable period in 2021. Clovis expects selling, general and
administrative expenses in the full year 2022 to be comparable to
2021.
Clovis reported a net loss for Q1 2022 of $60.2 million, or
($0.44) per share, compared to a net loss for Q1 2021 of $66.3
million, or ($0.64) per share. Net loss for Q1 2022 included
share-based compensation expense of $6.6 million, compared to $4.0
million for the comparable period of 2021.
Clovis had $122.2 million in cash and cash equivalents as of
March 31, 2022. During Q1 2022, the Company raised $28.6 million in
net proceeds through its “at-the-market” equity offering program.
Clovis remains focused on its liquidity position and is committed
to raising additional capital in the near term in order to fund its
operating plan for the next 12 months and beyond.
As of March 31, 2022, the Company had drawn $156.4 million under
the Sixth Street Partners, LLC (SSP) ATHENA clinical trial
financing and had up to $18.6 million available to draw under the
agreement to fund the expenses of the ATHENA trial.
Net cash used in operating activities was $58.5 million for Q1
2022, down 5% from the $61.9 million reported in Q1 2021. Cash burn
in Q1 2022 was $49.3 million, up 2% from $48.1 million in Q1 2021.
As costs for the ATHENA trial are reducing, SSP funding was $4.6
million lower in Q1 2022 vs Q1 2021.
Clovis Oncology Pipeline Highlights
ATHENA-MONO Successfully Achieved Primary PFS Endpoint; Data
to be Presented at ASCO 2022
The monotherapy portion of the ATHENA (GOG 3020/ENGOT-ov45)
trial (ATHENA-MONO) enrolled 538 women with high-grade ovarian,
fallopian tube, or primary peritoneal cancer. The primary efficacy
analysis evaluated two prospectively defined molecular sub-groups
in a step-down manner: 1) HRD-positive (inclusive of BRCAm tumors),
and 2) all patients randomized (intent-to-treat, or ITT) in
ATHENA-MONO.
Positive top-line data from the monotherapy portion of
ATHENA-MONO demonstrated Rubraca as maintenance treatment
successfully achieved the primary endpoint of significantly
improved investigator-assessed progression-free survival (PFS)
compared with placebo.
Benefit was observed in both primary efficacy analyses of
newly-diagnosed patients with advanced ovarian cancer following
successful treatment with platinum-based chemotherapy.
- The rucaparib arm successfully achieved statistical
significance over the placebo arm for the primary endpoint of PFS
in the homologous recombination deficiency (HRD-positive) patient
population with a hazard ratio of 0.47 (95% CI: 0.31-0.72). The
median PFS for these patients treated with rucaparib was 28.7
months vs 11.3 months among those who received placebo
(p=0.0004).
- Rucaparib also showed statistical significance over the placebo
arm for PFS for all 538 patients enrolled in the ATHENA-MONO
comparison with a hazard ratio of 0.52 (95% CI: 0.40-0.68). The
median PFS for all patients enrolled in ATHENA-MONO and treated
with rucaparib was 20.2 months vs 9.2 months among those who
received placebo (p<0.0001).
Benefit in PFS was also seen in the exploratory subgroups of
patients with BRCA mutant (BRCAm) tumors, those with BRCA wild
type, HRD-positive and HRD-negative tumors, and those whose
biomarker status could not be determined.
- The PFS endpoint in the exploratory subgroup of BRCAm
demonstrated a hazard ratio of 0.40 (95% CI: 0.21-0.75). The median
PFS for these patients treated with rucaparib was Not Reached vs
14.7 months for those who received placebo.
- The PFS endpoint in the exploratory subgroup of BRCA wild type
HRD-negative demonstrated a hazard ratio of 0.65 (95% CI:
0.45-0.95). The median PFS for these patients treated with
rucaparib was 12.1 months vs. 9.1 months for those who received
placebo.
- The PFS endpoint in the exploratory subgroup of BRCA wild type
HRD-positive demonstrated a hazard ratio of 0.58 (95% CI:
0.33-1.01). The median PFS for these patients treated with
rucaparib was 20.3 months vs. 9.2 months for those who received
placebo.
- The PFS endpoint in the exploratory subgroup of patients whose
biomarker status could not be determined demonstrated a hazard
ratio of 0.39 (95% CI: 0.20-0.78). The median PFS for these
patients treated with rucaparib was 17.5 months vs. 8.9 months for
those who received placebo.
The safety of Rubraca observed in ATHENA-MONO was consistent
with both the current US and European labels. The most common (≥5%)
treatment-emergent grade 3/4 adverse events (TEAEs) among all
patients treated with rucaparib in the monotherapy portion of the
ATHENA study were anemia/decreased hemoglobin (28.7%), neutropenia
(14.6%), ALT/AST increase (10.6%), and thrombocytopenia (7.1%). The
discontinuation rate for TEAEs was 11.8% for rucaparib-treated
patients and 5.5% for the placebo arm. The rate of
treatment-emergent myelodysplastic syndrome (MDS)/acute myeloid
leukemia (AML) in the rucaparib arm was 0.2%, and no patients on
the placebo arm experienced treatment-emergent MDS/AML.
We presently intend to submit a supplemental New Drug
Application (sNDA) to the FDA and, subject to EMA discussions, a
Type II variation to the EMA for a first-line maintenance treatment
indication for women with advanced ovarian cancer who have
responded to first-line platinum-based chemotherapy. We are engaged
in discussions with FDA on the scope and timing of the submission,
and we expect that the regulatory agencies will review the overall
results as well as results by individual subgroups in making their
assessment.
The ATHENA-MONO data have been accepted as a late-breaker
abstract and will be presented in an oral session at the 2022 ASCO
Annual Meeting on June 6 in Chicago. Clovis Oncology plans to
provide an expanded description of the ATHENA-MONO study results,
including Kaplan-Meier curves and key secondary endpoints including
PFS results by blinded independent centralized review (BICR) and
other analyses.
Two Remaining Rubraca Phase 3 Study Readouts Expected in Next
12 Months
Top-line data from the ATHENA-COMBO portion of the ATHENA Phase
3 study in first-line maintenance treatment ovarian cancer setting
evaluating Rubraca plus Opdivo® (nivolumab) versus Rubraca
monotherapy are expected in the first quarter of 2023.
Top-line data from the TRITON3 trial, which is expected to serve
as the confirmatory study for Rubraca’s approval in metastatic
castration-resistant prostate cancer (mCRPC) as well as a potential
second-line label expansion, are now expected in the third quarter
of 2022 instead of the second quarter of 2022 based on a slower
than expected event count. TRITON3 is a Phase 3 study evaluating
Rubraca versus physician’s choice of chemotherapy or second-line
androgen deprivation therapy in patients with mCRPC with BRCA or
ATM mutations with a primary endpoint of radiologic PFS.
The timing for each Phase 3 data readout is contingent upon the
occurrence of the protocol-specified PFS events, and timing
estimates are based on event-based projections.
LuMIERE Phase 1/2 Study of FAP-2286 Enrolling Patients with
FAP-Positive Solid Tumors into Phase 1; Initial Phase 1 LuMIERE
Data to be Presented in an Oral Session at SNMMI 2022 Annual
Meeting
FAP-2286 is the first peptide-targeted radionuclide therapy
(PTRT) and imaging agent targeting fibroblast activation protein
(FAP) to enter clinical development and is the lead candidate in
Clovis Oncology’s targeted radiotherapy (TRT) development program.
The Phase 1 portion of the LuMIERE study, for which enrollment in
the third dose cohort has begun, is evaluating the safety of the
FAP-targeting investigational therapeutic agent and will identify
the recommended Phase 2 dose and schedule of lutetium-177 labeled
FAP-2286 (177Lu-FAP-2286). FAP-2286 labeled with gallium-68
(68Ga-FAP-2286) is being used as an investigational imaging agent
to identify patients with FAP-positive tumors appropriate for
treatment in LuMIERE. Initial Phase 1 data from LuMIERE will be
presented in an oral session at the SNMMI 2022 Annual Meeting on
June 14 in Vancouver, British Columbia. Once the Phase 2 dose is
determined, Phase 2 expansion cohorts are planned in multiple tumor
types and are expected to initiate in the fourth quarter of
2022.
Beyond Clovis’ commitment to developing 177Lu-FAP-2286, the
Company is also exploring an alpha-particle emitting compound, and
in March, Clovis initiated a development, manufacturing, and
services agreement with Evergreen Theragnostics to develop
actinium-225-labeled-FAP-2286 (225Ac-FAP-2286). Under the
agreement, Clovis and Evergreen intend to develop radiolabeling
chemistry and analytical methods for use in potential future
pre-clinical and clinical studies.
For more information about FAP-2286, TRT, or Clovis’ TRT
development program, click here.
Conference Call Details
Clovis will hold a conference call this morning, May 4, at 8:30
am ET, to discuss Q1 2022 results and provide an update on the
Company’s clinical development programs and regulatory and
commercial outlook. The conference call will be simultaneously
webcast on the Clovis Oncology website at clovisoncology.com, and
archived for future review. Dial-in numbers for the conference call
are as follows: US participants 888.440.4615, International
participants 646.960.0682, conference ID: 2259685.
About Rubraca (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and
PARP3 being developed in multiple tumor types, including ovarian
and prostate cancers, as monotherapy and in combination with other
anti-cancer agents. Exploratory studies in other tumor types are
also underway. Clovis holds worldwide rights for Rubraca.
In the United States, Rubraca is approved for the maintenance
treatment of adult patients with recurrent epithelial, ovarian,
fallopian tube, or primary peritoneal cancer who are in a complete
or partial response to platinum-based chemotherapy. Rubraca is also
approved in the United States for the treatment of adult patients
with deleterious BRCA mutation (germline and/or somatic) associated
epithelial ovarian, fallopian tube, or primary peritoneal cancer
who have been treated with two or more chemotherapies and selected
for therapy based on an FDA-approved companion diagnostic for
Rubraca. Additionally, Rubraca is approved in the US for the
treatment of adult patients with a deleterious BRCA mutation
(germline and/or somatic)-associated metastatic
castration-resistant prostate cancer (mCRPC) who have been treated
with androgen receptor-directed therapy and a taxane-based
chemotherapy. Select patients for therapy based on an FDA-approved
companion diagnostic for Rubraca. This indication is approved under
accelerated approval based on objective response rate and duration
of response. Continued approval for this indication may be
contingent upon verification and description of clinical benefit in
confirmatory trials. The TRITON3 clinical trial is expected to
serve as the confirmatory study for the Rubraca accelerated
approval in mCRPC.
In Europe, Rubraca is approved for the maintenance treatment of
adults with platinum-sensitive relapsed, high-grade epithelial,
ovarian, fallopian tube, or primary peritoneal cancer who are in
response (complete or partial) to platinum-based chemotherapy.
Rubraca is also approved in Europe for the treatment of adult
patients with platinum sensitive, relapsed or progressive, BRCA
mutated (germline and/or somatic), high-grade epithelial ovarian,
fallopian tube, or primary peritoneal cancer, who have been treated
with two or more prior lines of platinum-based chemotherapy, and
who are unable to tolerate further platinum-based chemotherapy.
Rubraca is an unlicensed medical product outside the US and
Europe.
About FAP-2286
FAP-2286 is a clinical candidate under investigation as a
peptide-targeted radionuclide therapy (PTRT) and imaging agent
targeting fibroblast activation protein (FAP). FAP-2286 consists of
two functional elements; a targeting peptide that binds to FAP and
a site that can be used to attach radioactive isotopes for imaging
and therapeutic use. High FAP expression has been shown in
pancreatic ductal adenocarcinoma, salivary gland, mesothelioma,
colon, bladder, sarcoma, squamous non-small cell lung, squamous
head and neck cancers, and cancers of unknown primary. High FAP
expression was detected in both primary and metastatic tumor
samples and was independent of tumor stage or grade. Clovis holds
US and global rights for FAP-2286 excluding Europe, Russia, Turkey,
and Israel.
FAP-2286 is an unlicensed medical product.
About Targeted Radionuclide Therapy
Targeted radionuclide therapy is an emerging class of cancer
therapeutics, which seeks to deliver radiation directly to the
tumor while minimizing delivery of radiation to normal tissue.
Targeted radionuclides are created by linking radioactive isotopes,
also known as radionuclides, to targeting molecules (e.g.,
peptides, antibodies, small molecules) that can bind specifically
to tumor cells or other cells in the tumor environment. Based on
the radioactive isotope selected, the resulting agent can be used
to image and/or treat certain types of cancer. Agents that can be
adapted for both therapeutic and imaging use are known as
“theranostics.” Clovis is developing a pipeline of novel, targeted
radiotherapies for cancer treatment and imaging, including its lead
candidate, FAP-2286, an investigational peptide-targeted
radionuclide therapeutic (PTRT) and imaging agent, as well as three
additional discovery-stage compounds.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing, and commercializing innovative anti-cancer
agents in the US, Europe, and additional international markets.
Clovis Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops, with partners, for
those indications that require them, diagnostic tools intended to
direct a compound in development to the population that is most
likely to benefit from its use. Clovis Oncology is headquartered in
Boulder, Colorado, with additional office locations in the US and
Europe. Please visit www.clovisoncology.com for more
information.
To the extent that statements contained in this press release
are not descriptions of historical facts regarding Clovis Oncology,
they are forward-looking statements reflecting the current beliefs
and expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Examples of forward-looking statements contained in this press
release include, among others, statements regarding our future
financial and operating performance, our need to raise additional
capital to fund our operating plan and to continue as a going
concern, our business plans or prospects, our expectations
regarding the impact of COVID-19 on our business operations and
results, including future revenues, supply and distribution of our
clinical trial supplies and commercial product supplies, our
expectations regarding our ability to maintain the enrollment and
conduct of our clinical trials and other development activities,
expectations concerning future regulatory activities, expectations
for submission of regulatory filings, our plans to present final or
interim data on ongoing clinical trials, our plans to submit
additional data to, or meet with, the FDA with respect to the
status of or plans for ongoing or planned trials, the timing and
pace of commencement of enrollment in and conduct of our clinical
trials and the cost of certain trials, including those being
considered, planned or conducted in collaboration with partners,
our plans for commencement of additional planned trials, the
potential results of such clinical trials and the potential for
marketing authorizations for new indications, changes in drug
supply timing and costs and other expenses and statements regarding
our expectations of the supply of free drug distributed to eligible
patients and our expectations regarding the funding that may be
available to us under the agreement with Sixth Street Partners,
LLC. Such forward-looking statements involve substantial risks and
uncertainties that could cause our future results, performance, or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, factors that impact our
ability to raise capital, which are outside of our control,
including whether additional funding will be available on
acceptable terms, or at all, unpredictable market conditions and
volatility in our stock price, our ability to generate positive
data from our clinical studies, and the need for our stockholders
to approve an amendment to our certificate of incorporation to
increase the number of shares of common stock that we are
authorized to issue; the impacts of the COVID-19 pandemic and
disruption related to efforts to mitigate its spread on our
business, results of operations or financial condition, including
impacts on the vendors or distribution channels in our supply
chain, impacts on our contract manufacturers’ ability to continue
to manufacture our products, impacts on our ability to continue our
development activities, impacts on the conduct of our clinical
trials, including with respect to enrollment rates, availability of
investigators and clinical trial sites or monitoring of data and
impact on the ability and timing of our field personnel to conduct
their activities with health care providers, the timing and extent
of recovery from the impact of COVID-19, the uncertainties inherent
in the effect our future revenues or expenses may have on our cash
position, the market potential of our approved drug, including the
performance of our sales and marketing efforts and the success of
competing drugs and therapeutic approaches, changes in gross-to-net
or free drug provided through our patient assistance program, the
availability of reimbursement and insurance coverage, the
performance of our third-party manufacturers, whether our clinical
development programs for our drug candidates and those of our
partners can be completed on time or at all, whether future study
results will be consistent with study findings to date and whether
future study results will support continued development or
regulatory approval, the corresponding development pathways of our
companion diagnostics, the timing of availability of data from our
clinical trials and the results, the initiation, enrollment, timing
and results of our planned clinical trials, the risk that final
results of ongoing trials may differ from initial or interim
results as a result of factors such as final results from a larger
patient population may be different from initial or interim results
from a smaller patient population, actions by the FDA, the EMA or
other regulatory authorities regarding data required to support
drug applications and whether to accept or approve drug
applications that may be filed, their interpretations of our data
and agreement with our regulatory approval strategies or components
of our filings, including our clinical trial designs, conduct and
methodologies, as well as their decisions regarding drug labeling,
reimbursement and pricing, and other matters that could affect the
development, approval, availability or commercial potential of our
drug candidates or companion diagnostics. Clovis Oncology does not
undertake to update or revise any forward-looking statements. A
further description of risks and uncertainties can be found in
Clovis Oncology’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
reports on Form 10-Q and Form 8-K.
CLOVIS ONCOLOGY, INC CONSOLIDATED
FINANCIAL RESULTS (Unaudited, in thousands, except per share
amounts)
Clovis remains focused on its liquidity position and recognizes
that it will need to raise additional capital in the near term to
fund its operating plan for the next 12 months and to continue as a
going concern. The accompanying condensed consolidated financial
statements have been prepared on a basis which assumes that Clovis
will continue as a going concern. A more detailed discussion of
Clovis’ liquidity position and management’s plans and risk related
thereto will be set forth in Clovis’ Quarterly Report Form 10-Q
that Clovis anticipates will be filed with the SEC later today. The
Company included in its Annual Report on Form 10-K, and expects to
include a disclosure within its Quarterly Report on Form 10-Q in
respect of certain conditions concerning the Company’s overall
liquidity position that raise substantial doubt about its ability
to continue as a going concern.
Three Months Ended March
31,
2022
2021
Revenues: Product revenue
$
34,247
$
38,053
Operating expenses: Cost of
sales - product
8,070
8,268
Cost of sales - intangible asset amortization
1,343
1,343
Research and development
42,250
52,805
Selling, general and administrative
29,213
29,941
Other operating expenses
3,730
3,707
Total expenses
84,606
96,064
Operating loss
(50,359
)
(58,011
)
Other income (expense): Interest
expense
(9,100
)
(8,037
)
Foreign currency loss
(978
)
(546
)
Other income
148
183
Other income (expense), net
(9,930
)
(8,400
)
Loss before income taxes
(60,289
)
(66,411
)
Income tax benefit
120
134
Net loss
$
(60,169
)
$
(66,277
)
Basic and diluted net loss per common share
$
(0.44
)
$
(0.64
)
Basic and diluted weighted-average common
shares
138,205
104,246
CONSOLIDATED BALANCE SHEET DATA (In thousands)
March 31, 2022
(Unaudited) December 31, 2021
Cash and cash equivalents
$
122,241
$
143,428
Working capital
63,703
72,873
Total assets
451,529
472,833
Convertible senior notes
437,284
436,772
Common stock and additional paid-in capital
2,677,109
2,641,841
Total stockholders' deficit
(303,306
)
(278,840
)
Other Data (Unaudited, in thousands)
Three Months Ended March
31,
2022
2021
Net cash used in operating activities
$
(58,495
)
$
(61,890
)
Share Based Compensation Expense
6,632
4,039
RECONCILIATION OF NET CASH
USED IN OPERATING
ACTIVITIES TO CASH
BURN
(Unaudited, in thousands)
Three Months Ended March
31,
2022
2021
Net cash used in operating activities
$
(58,495
)
$
(61,890
)
Adjustments: Proceeds from borrowings under financing
agreement
9,221
13,802
Cash burn
$
(49,274
)
$
(48,088
)
Net cash used in investing activities
$
(62
)
$
(118
)
Net cash provided by financing activities
$
37,857
$
13,376
To supplement our financial statements prepared in accordance
with U.S. GAAP, we monitor and consider cash burn, which is a
non-U.S. GAAP financial measure. This non-U.S. GAAP financial
measure is not based on any standardized methodology prescribed by
U.S. GAAP and is not necessarily comparable to similarly-titled
measures presented by other companies. We define cash burn as net
cash used in operating activities less proceeds from borrowings
under financing agreement with Sixth Street specifically related to
our Phase 3 ATHENA trial. We believe cash burn to be a liquidity
measure that provides useful information to management and
investors about the amount of cash consumed by the operations of
the business including proceeds from borrowings under the Sixth
Street financing agreement, which specifically offsets the costs of
our ATHENA trial. A limitation of using this non-U.S. GAAP measure
is that cash burn does not represent the total change in cash and
cash equivalents for the period because it excludes all other cash
provided by or used for other investing and financing activities.
We account for this limitation by providing information about our
investing and financing activities in the statements of cash flows
in our financial statements and by presenting cash flows from
investing and financing activities in our reconciliation of cash
burn. In addition, it is important to note that other companies,
including companies in our industry, may not use cash burn, may
calculate cash burn in a different manner than we do or may use
other financial measures to evaluate their performance, all of
which could reduce the usefulness of cash burn as a comparative
measure. Because of these limitations, cash burn should not be
considered in isolation from, or as a substitute for, financial
information prepared in accordance with U.S. GAAP.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504005362/en/
Breanna Burkart (303) 625-5023 bburkart@clovisoncology.com
Anna Sussman (303) 625-5022 asussman@clovisoncology.com
Clovis Oncology (NASDAQ:CLVS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Clovis Oncology (NASDAQ:CLVS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024